Pfizer stock
PFENYSEPfizer Inc., HealthcareISIN US7170811035
61Score 61 out of 100, Neutral
Price and trend
74 / 100
Price history
+11% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 6.9% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 39).
The price is 6.4% below its 52-week high. Largest decline in 20 years: 65% (December 2021 to April 2025).
Chart figures for advanced users
- SMA 50$28.80
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$26.97
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)39
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$23.67
- The lowest closing price of the last twelve months.
- Resistance$30.79
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Pfizer Inc. belongs to the Drug Manufacturers (General) industry (United States) and, with a market value of $164.33B, is number 11 of 27 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $62.58B (down 1.6% year on year) and earnings of $7.77B (down 3.2%).
- For fiscal 2026, analysts expect on average revenue of $63.02B (up 0.7%) and adjusted earnings per share of $3.03 (down 6.2%).
Show more
- MEQIRI Score 61 out of 100 (Neutral): rank 270 of 714 in Healthcare, median 53.
- The P/E is 41.1 because earnings over the last twelve months collapsed; on the expected earnings of the next twelve months it is 9.8 (Drug Manufacturers (General) median 25.6). The P/E therefore does not count in the score.
- Our model puts fair value at $16.80, with the price 75% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 292% of earnings over the last 12 months.Fundamentals 89
- High dividend yieldDividend yield 5.84%, Drug Manufacturers (General) median 2.14%.Capital allocation 65
- Reliable dividendNo dividend cut for 17 years.Capital allocation 65
Weaknesses
- Above fair valuePrice 75% above the fair value of $16.80.Valuation 19
- Earnings per share fallingDown 23.4% a year since 2021.Growth 36
- Analysts expect falling earningsDown 8.1% a year through 2028 (estimates from 13 analysts).Growth 36
Its standout strengths are fundamentals and momentum, while growth and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 62 to 61.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among the 100 largest stocks.
From 2016 to 2025, 4 in 100 such stocks fell 30% or more within a year, against a group average of 9 in 100.
What lowers it
- solid fundamentals
- calm price action
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $14.00 and expensive above $21.00 (uncertainty low, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $14.34, at 7.8% it would be $20.45.
Valuation metrics
From the cash-flow model alone; after a one-off collapse in earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 27 Sep 2026, revenue rose 1.3% on the twelve months before. Revenue has changed sharply in recent years: $62.58B in 2025 after $101.18B in 2022.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 74%, operating 28%, net 12%. Last 12 months: net 6%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 2 Feb 2027in 82 days
- Last reported
- 3 Nov 2026EPS reported $0.87 (expected $0.74)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $3.03+2.4%
- Revenue
- $63.02B+1.2%
- Earnings per share
- $2.94+1.3%
- Revenue
- $60.63B+1.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +3.1%Midpoint of 2026 revenue guidance raised, adjusted EPS guidance of $2.80 to $3.00 reaffirmed; an additional $1 billion of cost savings expected through 2029.
“We now expect an additional $1 billion in savings from our ongoing cost realignment program, powered in part by rapid advancement of technology. Net cost savings from these programs are now expected to total $6.7 billion through 2029.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
3 insiders bought on the open market between 5 Aug 2026 and 12 Aug 2026, $2.96M in total. One insider sold, $134,661 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Pfizer
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 61
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
- AstraZenecaAZN $287.66B73
- AmgenAMGN $253.21B77
- Gilead SciencesGILD $210.52B58
- Novo NordiskNOVO-B.CO $178.97B79
- Bristol-Myers SquibbBMY $128.59B71
- SanofiSAN.PA $115.46B67
- GSKGSK $101.43B70
- Chugai Pharmaceutical4519.T $73.85B78
ETFs that hold Pfizer
Held by 120 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| VanEck Morningstar Developed Markets Dividend Leaders UCITS ETFVDIV | 4.34% | 0.38% | €10.52B |
| Invesco S&P 500 High Dividend Low Volatility UCITS ETFHDLV | 3.66% | 0.30% | €357.87M |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 2.55% | 0.15% | €3.27B |
Show 5 more
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 2.54% | 0.12% | €1.34B |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 2.54% | 0.15% | €592.11M |
| UBS Factor MSCI USA Prime Value Screened UCITS ETF USD disUBUS | 2.47% | 0.25% | €127.84M |
| iShares MSCI USA Quality Dividend Advanced UCITS ETFQDVD | 2.44% | 0.35% | €777.04M |
| iShares Dow Jones U.S. Select Dividend UCITS ETF (DE)EXX5 | 2.39% | 0.31% | €415.03M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 8 Nov 2024)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.